Cancer Does Not Have to Be a Death Sentence
Canine cancer is a heartbreaking diagnosis that affects millions of beloved pets worldwide. In fact, it’s one of the biggest unmet needs in veterinary medicine. As advancements in our field continue to evolve, FidoCure emerges as a groundbreaking solution, offering a revolutionary approach to treating canine cancer. By harnessing the power of genomic testing, FidoCure provides targeted therapies that are transforming the landscape of canine cancer care.
FOR IMMEDIATE RELEASE
Dr. Ehrhart shares insight from her current work in comparative aging research and highlights its intersection with cancer and musculoskeletal research in veterinary medicine.
Genomics is fast becoming an essential part of veterinary oncology. It touches upon all aspects of practice, from diagnostics to therapeutics. Genetic information can be incredibly useful in terms of making a more accurate diagnosis or making a more precise prognosis, or even determining what therapy to use or what order to use different therapies.
We welcomed Dr. Neal Mauldin, Chief Medical Officer, PetCure Oncology to our webinar series. He is one of the only triple-boarded veterinarians, certified in the field of internal medicine, medical oncology and radiation oncology.
Canine cancer diagnoses can be devastating and demoralizing. While research and studies for human cancer have brought us a long way when it comes to treatment and instilling hope for our loved ones, the same can’t necessarily be said for the world of pet medicine. Despite this, there are many passionate veterinarians and vet oncologists out there who are helping to move the needle on pet cancer research and treatment. Taking cues from the progress made on human cancer treatment, FidoCure uses genomic testing to match dogs with targeted therapies for their specific cancer profile. Not only does this process increase the chances of a better prognosis, but it helps vets and vet oncologists deduce effective therapies for future canine cancer cases. FidoCure has already proven that a prognosis can be improved using targeted therapies. Take hemangiosarcoma for instance…
DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy.
© Copyright 2018-2022 OHC, All rights reserved